Compare Freeport-McMoRan Inc (FCX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Tango Therapeutics Inc. — how do they compare? Freeport-McMoRan Inc trades at $69.01 (market cap $104.00B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Freeport-McMoRan Inc is far larger — about 27.7× Tango Therapeutics Inc.'s market cap, and Freeport-McMoRan Inc pays a 0.83% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 70 Days and Tango Therapeutics Inc. for 0 Days on average.
| FCX | TNGX | |
|---|---|---|
Market Cap | $104.00B | $3.75B |
Volume | 7,316,762 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $32.90 |
52-Week Low | $38.65 | $7.50 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $110.28B | $2.77B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, down 5.01% today, but maintains strong technical momentum with bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Copper demand fundamentals remain robust, driven by AI infrastructure needs, while FCX's expansion projects position it for growth. Analyst consensus remains strongly bullish with a $73.27 price target.
FCX presents a compelling investment case with strong copper demand tailwinds and consistent earnings outperformance. However, rising production costs and a high P/E ratio of 35.5 warrant caution. The stock offers exposure to copper's structural deficit while carrying execution risks from expansion projects and commodity price volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
